This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Japanese Association for Clinical Oncology | |
|---|---|
| Name | Japanese Association for Clinical Oncology |
| Formation | 1964 |
| Type | Professional association |
| Headquarters | Tokyo |
| Region served | Japan |
| Membership | oncologists, surgeons, hematologists |
| Leader title | President |
Japanese Association for Clinical Oncology is a professional society that represents physicians and healthcare professionals involved in cancer diagnosis and treatment in Japan. The association engages with academic hospitals such as National Cancer Center Hospital (Japan), universities including The University of Tokyo, and clinical research groups like Japan Clinical Oncology Group to promote standards for oncology care, collaborative trials, and continuing professional development. It interfaces with regulatory and policy bodies such as the Ministry of Health, Labour and Welfare (Japan) and participates in international forums including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the Union for International Cancer Control.
The association was founded in 1964 amid postwar expansion of specialized medical societies that included contemporaries such as the Japanese Society of Internal Medicine, the Japanese Surgical Society, and the Japanese Cancer Association. Early leaders drew from academic centers like Kyoto University Hospital and Osaka University Hospital, collaborating with research institutes such as the National Cancer Center and clinical trial networks exemplified later by the Japan Clinical Oncology Group. Over subsequent decades the association responded to shifts initiated by events such as the approval of new anticancer agents by the Pharmaceuticals and Medical Devices Agency (Japan), the introduction of targeted therapies exemplified by trastuzumab approvals, and participation in multicenter trials modeled on designs from the National Cancer Institute (United States). Milestones included establishment of specialty certification frameworks similar to those developed by the American Board of Internal Medicine and the launch of national guidelines paralleling efforts by the National Institute for Health and Care Excellence.
The association's governance parallels structures found in academic organizations like Japan Society of Clinical Oncology and consists of an elected council, executive officers, and standing committees reflecting disciplines such as medical oncology, surgical oncology, and radiation oncology. Leadership rotations have included presidents drawn from Keio University School of Medicine, Tohoku University Hospital, and Nagoya University Hospital. Committees coordinate with bodies such as the Japan Society of Hematology and the Japanese Breast Cancer Society for cross-specialty standards and with regulatory stakeholders like the Pharmaceuticals and Medical Devices Agency (Japan) for safety reporting. The association maintains ethics oversight similar to institutional review boards at centers like Hokkaido University Hospital and aligns conflict-of-interest policies with international norms from organizations including World Health Organization and International Committee of Medical Journal Editors.
Membership comprises clinicians from university hospitals such as Sapporo Medical University Hospital, regional cancer centers like the Aichi Cancer Center, and community hospitals affiliated with the Japan Hospital Association. Members include specialists in medical oncology, pediatric oncology, hematology, thoracic surgery, and gynecologic oncology, with allied professionals from pharmacy departments, nursing services tied to institutions like St. Luke's International Hospital, and clinical trial coordinators. Professional activities include multicenter clinical trials in collaboration with the Japan Clinical Oncology Group, educational workshops mirroring curricula from the European School of Oncology, and advocacy for reimbursement policies interacting with agencies such as the Central Social Insurance Medical Council. The association fosters subspecialty boards similar to certification processes by the Japanese Board of Surgery and exchanges with international societies like ASCO and ESMO.
The association organizes an annual scientific meeting attended by delegations from institutions including The University of Tokyo Hospital, Kyushu University Hospital, and international partners such as MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center. Sessions cover topics ranging from clinical trials modeled on designs by the National Cancer Institute (United States) to translational research linked to work at the RIKEN research institute. The association publishes proceedings, clinical guidelines, and position statements in journals and platforms comparable to Cancer Science and collaborates with editorial outlets like The Lancet Oncology and Journal of Clinical Oncology for high-profile reports. Special issues have highlighted advances in targeted therapy following approvals for agents such as imatinib and immunotherapy developments related to pembrolizumab.
Educational programs include certificate courses for clinicians and nurses patterned after training from institutions like Johns Hopkins Hospital and Mayo Clinic, and guideline development committees produce consensus documents analogous to those from NCCN and ASCO. Research initiatives span investigator-initiated trials, pharmacoepidemiology studies collaborating with the Pharmaceuticals and Medical Devices Agency (Japan), and translational projects in partnership with university centers such as Osaka University and national laboratories like National Institute of Radiological Sciences. The association promotes data sharing consistent with standards from the Clinical Data Interchange Standards Consortium and coordinates biobanking efforts akin to programs at the National Cancer Center (Japan).
The association confers awards recognizing clinical research and service, modeled after prizes from societies like the Japanese Cancer Association and international awards such as the Lasker Award and Nobel Prize in Physiology or Medicine in terms of prestige for recipients. Awardees have included clinicians affiliated with universities such as Hiroshima University and research hospitals like Kobe University Hospital, honoring contributions in clinical trials, guideline authorship, and oncologic surgery innovations influenced by leaders in fields represented by organizations such as the Japanese Association of Thoracic Surgery and the Japan Society of Clinical Oncology.
Category:Medical associations based in Japan